Sulfuric Acid

Sulfuric Acid

SCHEMBL2009713

O.O.O.O.O.O.O=S(=O)([O-])[O-].[Na+].[Na+]

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
TSHR P16473 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
TP53 P04637 2/20 0.38
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
GMNN O75496 1/20 0.32
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32
THPO P40225 1/20 0.32
HBB P68871 1/20 0.32
PMP22 Q01453 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL20809 1.00 ALDH1A1 (0.55) ALDH1A1TSHRMEN1KMT2ATP53
Sulfuric Acid SCHEMBL5672709 1.00 ALDH1A1 (0.55) ALDH1A1TSHRMEN1KMT2ATP53
Sulfuric Acid SCHEMBL1463018 1.00 ALDH1A1 (0.55) ALDH1A1TSHRMEN1KMT2ATP53
Sulfuric Acid SCHEMBL16636 1.00 ALDH1A1 (0.55) ALDH1A1TSHRMEN1KMT2ATP53
Sulfuric Acid SCHEMBL1938250 1.00 ALDH1A1 (0.55) ALDH1A1TSHRMEN1KMT2ATP53
Sulfuric Acid SCHEMBL10582959 1.00 ALDH1A1 (0.55) ALDH1A1TSHRMEN1KMT2ATP53
Sulfuric Acid SCHEMBL9190441 1.00 ALDH1A1 (0.55) ALDH1A1TSHRMEN1KMT2ATP53
Sulfuric Acid SCHEMBL21294080 1.00 ALDH1A1 (0.55) ALDH1A1TSHRMEN1KMT2ATP53
Sulfuric Acid SCHEMBL22499921 1.00 ALDH1A1 (0.55) ALDH1A1TSHRMEN1KMT2ATP53
Sulfuric Acid SCHEMBL687089 1.00 ALDH1A1 (0.55) ALDH1A1TSHRMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115974043-A Production method of battery-grade nano sodium ferrous sulfate 河北惠尔信新材料股份有限公司 2023-04-18 CN claimed
CN-114941135-A Application of economic and environment-friendly chemical nickel plating stabilizer 金川集团镍盐有限公司 2022-08-26 CN claimed
CN-108094207-B Method for somatic embryogenesis and plant regeneration of slash pine 广东省林业科学研究院 2020-01-31 CN claimed
US-20260092034-A1 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME KULEON LLC (US) 2026-04-02 US disclosed
US-20250340513-A1 NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS KULEON LLC (US) 2025-11-06 US disclosed
US-12441683-B2 7-methyl indole analogs and dosage forms containing the same Kuleon, LLC (US) 2025-10-14 US disclosed
US-20250282722-A1 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME KULEON LLC (US) 2025-09-11 US disclosed
US-12344582-B2 Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression Kuleon, LLC (US) 2025-07-01 US disclosed
US-12275701-B2 Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators Kuleon, LLC (US) 2025-04-15 US disclosed
US-20250091991-A1 MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION Kuleon, LLC (US) 2025-03-20 US disclosed
US-12187678-B2 Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators Kuleon, LLC (US) 2025-01-07 US disclosed
US-20040204450-A1 Quinoline and quinoxaline compounds PFIZER INC 2004-10-14 US disclosed
WO-2004085401-A1 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY PFIZER PRODUCTS INC. (US) 2004-10-07 WO disclosed
EP-0859610-A4 IBOGAMINE CONGENERS ALBANY MEDICAL COLLEGE (US) 2002-05-15 EP disclosed
US-6211360-B1 DRUG ABRUSE THERAPY; PLANT EXTRACTS ALBANY MEDICAL COLLEGE 2001-04-03 US disclosed
EP-0859610-A1 IBOGAMINE CONGENERS ALBANY MEDICAL COLLEGE (US) 1998-08-26 EP disclosed
WO-1997005869-A1 IBOGAMINE CONGENERS ALBANY MEDICAL COLLEGE (US) 1997-02-20 WO disclosed
US-4513053-A Encapsulated phase change thermal energy storage materials and process PENNWALT CORPORATION (US) 1985-04-23 US disclosed
US-4505953-A COATING COMPACTED POWDER WITH LIQUID, AND CURING PENNWALT CORPORATION (US) 1985-03-19 US disclosed
US-4504402-A Encapsulated phase change thermal energy _storage materials PENNWALT CORPORATION (US) 1985-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092034-A1 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME HTR2C, HTR7, HTR6 ALDH1A1 3084/4885TSHR 186/4885MEN1 3416/4885
US-20250282722-A1 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME HTR7, HTR2C, HTR1A ALDH1A1 2395/4885TSHR 397/4885MEN1 1349/4885
US-12441683-B2 7-methyl indole analogs and dosage forms containing the same HTR7, HTR2C, HTR1A ALDH1A1 2395/4885TSHR 397/4885MEN1 1349/4885
US-12275701-B2 Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators HTR2A, HTR2C, HTR1A ALDH1A1 2952/4885TSHR 814/4885MEN1 3560/4885
US-12187678-B2 Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators HTR2C, HTR2A, HTR3B ALDH1A1 3735/4885TSHR 334/4885MEN1 3844/4885
US-20250340513-A1 NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS HTR2A, HTR2C, HTR3A ALDH1A1 2809/4885TSHR 786/4885MEN1 3802/4885
US-20040204450-A1 Quinoline and quinoxaline compounds LDLR, APOB, PON1 ALDH1A1 3034/4885TSHR 3528/4885MEN1 2399/4885
US-12344582-B2 Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression HTR2A, HTR2C, HTR3A ALDH1A1 2621/4885TSHR 457/4885MEN1 3910/4885
US-20250091991-A1 MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION HTR2A, HTR2C, HTR3A ALDH1A1 2621/4885TSHR 457/4885MEN1 3910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.